Establishing a technical collaboration with Japan's National Cancer Center and Lymphotec Inc.

In 2015, Lukas Biomedical invested and spent nearly two years to exclusively sign an agreement with Japan's Lymphotec Inc. for the 'Immune cell culture technology of activated lymphocyte therapy'. This technology has completed Phase III clinical trials in Japan and was transferred to South Korea, where it received marketing approval in 2016 under the product name 'Immuncell-LC'. At the present, nearly ten thousand clinical treatment cases related to this technology have been accumulated in Japan and South Korea.
Lukas Biomedical has transferred Japanese technology back to Taiwan, allowing cancer patients to receive top-tier cancer cell therapy domestically without having to travel abroad.

Note: Lymphotec Inc. of Japan was founded in 1999 by Dr. Teruaki Sekine, Principal Investigator of the National Cancer Center Research Institute.
 
ALL_fac_24E31_kM672jhj6U

Memory T cells are crucial in cancer treatment

Immunotherapy is the new trend in cancer treatment today. Cancer immunotherapy helps the immune system identify cancer cells and strengthens the immune response to destroy tumors.
T cell immunotherapy, in particular, strengthens and activates the T cells within the human body. Memory T cells have unique specificity and memory. While effector T cells diminish and retreat after attacking cancer cells, memory T cells persist in the body and retain the characteristics of the tumor. Upon the tumor's reappearance, these memory T cells can promptly eliminate it. 
The actual procedure involves extracting blood from the patient, using a GTP laboratory to cultivate and activate a large number of immune T cells from the blood, and then reintroducing these activated T cells back into the patient’s body to fight cancer cells.

 
ALL_fac_24G22_0UuEwgVdUB

The Advantages of T Cells, the top tumor killers

LuLym, the core cancer-fighting technology of Lukas Biomedical, utilizes T cells from the immune system to treat cancer. T cells are the most abundant group of cells in the adaptive immune system. They can be categorized into many types based on their function and surface markers (such as CD4+ and CD8+). The primary T cells used for cancer treatment are helper T cells (such as CD4+ helper T cells, Th) and cytotoxic T cells (CD8+ cytotoxic T cells, Tc or CTL). Since helper T cells have CD4+ molecules on their surface, they are called CD4+ T cells. These cells alert other immune units to enemy invasion and have memory properties. Therefore, when they encounter specific cancer cells again, they can immediately recognize them and activate the immune system to respond. They secrete cytokines to regulate the immune system.
Cytotoxic T cells, named CD8+ T cells due to the CD8+ molecules on their surface, act as a specialized attack force capable of recognizing and eliminating specific enemies.

  • Antigen-presenting cells (APCs) display peptide antigens on their surface through major histocompatibility complex (MHC) molecules, which specifically bind to receptors on CD4+ T cells, thereby triggering an immune response. 
    When interleukin-12 (IL-12) is secreted, it stimulates CD4+ T cells to differentiate into Th1 cells, promoting the release of interferon-gamma (IFN-γ), which in turn drives macrophages and cytotoxic T lymphocytes (CTLs) to kill infected cells. CTLs release granzymes and perforin into infected cells, inducing apoptosis.
  • Interleukin-4 (IL-4) induces the differentiation of cells into Th2 cells, which support B cells in producing antibodies to combat infection.

In accordance with the General Data Protection Regulation (GDPR) enforced by the European Union, we are committed to protecting your personal data and providing you with control over it.
By clicking "Accept All," you consent to our use of cookies to enhance your experience on this website, assist us in analyzing website performance and usage, and enable us to deliver relevant marketing content. You can manage your cookie settings below. By clicking "Confirm," you agree to adopt the current settings.

Manage Cookies

Privacy preferences

In accordance with the General Data Protection Regulation (GDPR) enforced by the European Union, we are committed to protecting your personal data and providing you with control over it.
By clicking "Accept All," you consent to our use of cookies to enhance your experience on this website, assist us in analyzing website performance and usage, and enable us to deliver relevant marketing content. You can manage your cookie settings below. By clicking "Confirm," you agree to adopt the current settings.

Privacy Policy

Manage preferences

Necessary cookie

Always on

The website cannot function without these cookies, and you cannot disable them in our system. These cookies are typically set in response to actions you take, such as setting your privacy preferences, logging in, or filling out forms. You can set your browser to block or alert you about these cookies, but this may cause some parts of the website to not work properly.